ObjectiveThis study was performed to investigate the safety and efficacy of oral paracetamol versus oral ibuprofen in the treatment of patent ductus arteriosus (PDA) in premature infants.MethodsPremature infants with PDA with a gestational age of ≤32 weeks or birth weight of ≤1500 g were included in this randomized study.ResultsA total of 120 premature infants fulfilled the inclusion criteria. Of these 120 infants, 34 fulfilled the treatment criteria and 22 were finally randomized. We found no significant difference in the mortality or primary closure rates between the two groups. We also found no significant difference in the short-term neonatal outcomes.ConclusionsEither oral paracetamol or oral ibuprofen can be used safely and effectively to treat PDA in premature infants.

Background The aim of this study was to investigate the risk factors for acquisition of extended spectrum β‐lactamase (ESBL)‐producing bacteria in community‐acquired urinary tract infection (UTI) and to evaluate their antimicrobial resistance. Methods The medical records of hospitalized children were retrospectively evaluated. Children with ESBL‐producing bacteria UTI were matched with controls with non‐ESBL‐producing bacteria UTI of the same age and gender. Results A total of 243 patients with community‐acquired UTI in a 5 year period were evaluated, of whom 46% had UTI caused by ESBL bacteria. Seventy‐seven cases were matched with 77 controls. There were no significant differences in the clinical presentation between the two groups apart from a longer hospital stay in the ESBL group (9.1 ± 5.5 days vs 8.0 ± 4.4 days, P = 0.013). Significant potential risk factors for ESBL‐UTI were previous use of antibiotics in the last 3 months, previous hospitalization in the last 3 months, history of recurrent UTI, and presence of renal anomalies. On logistic regression analysis, history of previous hospitalization in the last 3 months (OR, 3.83; 95%CI: 1.49–9.84) was identified as an independent significant risk factor for ESBL‐UTI. There was a significantly higher resistance to amoxicillin‐clavulanate, amikacin, gentamycin and quinolones in the ESBL group compared with the control group. Conclusion Recognizing the risk factors for ESBL‐UTI helps to identify the high‐risk cases and enables proper management.

Purpose: Very low birth weight infants (VLBWI) are the most fragile group of neonates with high rate of mortality and morbidity. Neonatal mortality rate in Jordan is still high. This is the first study from Jordan that aims to assess VLBWI mortality rate and the factors contributed to it and to report on the short outcomes and morbidities of those newborns in comparison to other countries to identify potential areas of improvement. Methods:A prospective study of all newborns with birth weight 500-1500 g, admitted to our level three neonatal intensive care unit (NICU) at Jordan university hospital over 14 months period. The results were compared to reports from other countries. Results:The study included 71 neonates admitted to our neonatal intensive care weighing from 500-1500 g during the study period. Most of them (88.7%) were inborn infants. Gestational ages mean ± SD was 28.6 ± 2.3 week. Birth weights mean ± SD was 1086.7 ± 262 g. Mortality rate was 35.2%. Short outcomes of survivors are for CLD 4.2%, sever ROP 3.8%, proven NEC 2.8%, PVL 1.9% and sever IVH rate was 10.6%. Conclusions:Mortality rate in our cohort is high. Multiple factors are involved. The care of very low birth infants in Jordan needs a lot of efforts to decrease mortality and improve morbidities. This is a prospective single center study. A multicenter study is needed that involves all health sectors in Jordan.

No abstract